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Abstract 
AIM: To measure the level of Systemic Lupus Erythematosus awareness among visitors in PHC at KAMC and to 
explores the factors which influence the Systemic Lupus Erythematosus awareness. 
METHODS: The study was a cross-sectional study conducted between February and September 2018 in four 
primary health care centers belong to King Abdulaziz Medical City. The study participants were male and female 
adult visitors to the centers` age from 18 to 60 years of age. The sample size was 400 participants. The 
participants were enrolled via a random convenience sampling method. Study data was collected using a self-
administered questionnaire. Analytic statistics were done using the Chi-square (
2
) test for associations and/or the 
difference between two categorical variables. A P-value ≤ 0.05 was considered statistically significant. 
RESULTS: The awareness about Systemic Lupus Erythematosus among male and female was not statistically 
significant as (P = 0.304), but there was a statistically significant difference according to education level. Visitors 
with high school education are aware of Systemic Lupus Erythematosus than those with a lower level of education 
(Primary & Middle school) who are not aware of the Systemic Lupus Erythematosus by (P = 0.023). 
CONCLUSION: The study shows that this survey is valuable and beneficial to the community as it helps people to 
assess their knowledge about Systemic Lupus Erythematosus and become aware of this disease, as well as 
awareness of Systemic Lupus Erythematosus should be promoted among the community. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Systemic lupus erythematosus (SLE) is a 
chronic inflammatory autoimmune disease that occurs 
when the immune system assaults the tissues of the 
body and its organs. Systemic means that SLE can 
affect the body’s various organs, including the skin, 
joints, brain, blood cells, kidneys, lungs, and heart. 
Lupus refers to the butterfly rash on the patient’s face, 
which is similar to the whitish outline marking on the 
middle of wolves’ faces. Erythematosus means the 
rash is reddish to purplish in color. Accordingly, four 
types of lupus can be identified: systemic lupus 
erythematosus, neonatal lupus, drug-induced lupus, 
and cutaneous lupus erythematosus. However, lupus 
erythematosus is the most common classification [1], 
[2]. 
The epidemiological studies was estimated 
that the prevalence of SLE was 241 per 100,000 
people in North America which is the highest and the 
lowest incidence was 0.3 per 100,000 person yearly 
noticed in South Africa which is the lowest. SLE 
affected more women than men for all age and ethnic 
groups. Women of reproductive age (15-45) are often 
affected, and the rate of females to males is 9 to 1 [1], 
[2], [3]. 
Likewise, scientists trust that human genetic 
studies will structure our understanding of the premise 
of individual hereditary vulnerability to SLE. These 
studies will help to detect the person who will have a 
high probability of having SLE in the future [1]. 
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Treatment of SLE will help to control disease 
progression and inhibit further complications. 
However, at the moment, there is no definitive 
medication or drug for treating SLE. SLE is usually 
very active when diagnosed for the first time. At this 
stage, high doses of drugs like glucocorticoids may be 
required to restrain the disease’s progression and 
stop organ harm, and this is the cornerstone of the 
treatment. However, despite advanced treatment 
SLE-associated infection and renal failure still 
increase mortality and this remains a major burden in 
management plans for patients [5], [6].
 
Addressing patient worries and fears about 
drug therapy, including treatment costs, side effects, 
and complications can increase the treatment 
adherence, fulfillment, and enhanced wellbeing results 
alongside psychological and behavioral interventions, 
which can be effective for decreasing weariness as 
well as enhancing strength in patients with SLE. 
Social help can assist patients with SLE accomplish 
positive thinking and a feeling of becoming stronger. 
Despite numerous advances in the diagnosis 
and treatment of SLE and associated comorbid 
conditions, such as loss of physical, social, and 
emotional functioning, this disease remains a source 
of significant morbidity and mortality. Indeed, even 
with the expected changes in general mortality over 
the last five decades, a patient diagnosed at 20 years 
of age still has a one in six chance of dying by the age 
of 35 and a higher probability of a shortened lifespan; 
in addition, SLE has a severe and pervasive influence 
on patients’ self-esteem, resulting in emotional 
challenges, fear of rejection, stigmatization, social 
isolation, and loss of independence [8], [9]. 
On the other hand, there are some studies 
that stress the importance of raising awareness and 
educating the public about SLE by clarifying the 
nature of the disease, its direct causes, treatment 
methods, and control mechanisms; for example, 
awareness activities directed to both the overall 
society and health care workers in particular can 
advise them to reduce delays in diagnosis and ensure 
early transfer to specialist care. 
In Riyadh, Saudi Arabia a study conducted in 
2015 among students at King Saud University showed 
that the level of awareness about SLE among 
students is low. Workshops or campaigns are required 
to enhance awareness and correct misunderstandings 
[10].
 
In Taif, Saudi Arabia a study undertaken in 
2017 that involved many of the Kingdom’s regions 
reported a high prevalence of less than optimal 
awareness and knowledge of SLE among the Saudi 
adult population [11].
 
In India, a study (2017) among the general 
population to assess their SLE awareness and 
knowledge found that the majority of participants had 
insufficient knowledge of its status as a rare disease 
that occurs in the population [12]. 
A 2018 study conducted among students at 
King Faisal University in Al-Hassa, Saudi Arabia found 
that most students have low awareness and some 
misunderstandings regarding SLE. Awareness 
programs are presumed able to increase awareness 
about SLE, as these campaigns have confirmed that 
greater public awareness may be useful in managing 
and controlling the disease and its associated 
complications [13]. 
Along with awareness activity, qualitative 
research is thought to be able to elicit patient 
knowledge and viewpoints, such as patients’ 
philosophies, misconceptions about the disease, and 
perceptions about new therapy or interventions, 
including monoclonal antibodies (mAb) therapy or 
immuno-suppression medications [7]. 
The main aim of the study is to evaluate the 
awareness of SLE among patients to primary health 
care clinics at King Abdulaziz Medical City (KAMC) in 
Riyadh and highlight the factors that influence SLE 
awareness, health promotion, information needed, 
and educational support.  
 
 
Methods 
 
The study was a cross-sectional study 
conducted between February and September 2018 in 
four primary health care centers belonging to KAMC: 
the Health Care Specialty Center (HCSC); King 
Abdulaziz Housing Clinics (Iskan); the National Guard 
Comprehensive Specialized Clinic (NGCSC), and 
King Abdulaziz Housing Clinics (Dirab). 
Each of the four centers delivers primary 
curative and preventive health services, and consists 
of walk-in services, a minor emergency room setting, 
and an appointment booking system for patients to 
obtain treatment and counseling for acute and chronic 
medical conditions. The study participants were male 
and female adult visitors to the centers aged between 
18 and 60. 
The sample size was calculated by the 
Openepi website. The population of the KAMC-PHC 
as per the latest report was found to be around 
420,000 people in 2017. They were distributed as 
follows: 200,000 patients in the HCSC, 100,000 
patients in the NGCSC, 70,000 patients in King 
Abdulaziz Housing Clinics (Dirab), and 50,000 
patients in King Abdulaziz Housing Clinics, (Iskan). 
Using a 95% confidence interval and 5% margin of 
error, the calculated minimum sample size was 
expected to be 384, which was modified to 400 to 
compensate for incomplete questionnaires.  
The proportion of participants from each of 
the four centers was based on the clinic catchment 
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area as follows: HCSC serves a population of around 
200,000 people, thus accounts for approximately 
47.6% of the sample size, equal to 190 participants; 
NGCSC serves around 100,000 people, accounting 
for approximately 23.8% of the sample size, equal to 
95 participants; Dirab center serves around 70,000 
people, accounting for approximately 16.6% of the 
sample size, equal to 67 participants; and Iskan 
serves around 50,000 people, accounting for 
approximately 11.9% of the sample size, equal to 48 
participants. 
Study data were collected using a self-
administered questionnaire. The questionnaire used 
was developed by Sullivan [2], and was adopted by 
the researchers to meet the study main objectives 
after a literature review of similar studies.  
The questionnaire was written in simple 
Arabic, and included the following sections: 
demographic data, and questions about knowledge, 
attitudes, and beliefs regarding SLE. Two research 
experts revised the questionnaire, and a pilot study 
was conducted with ten participants to confirm and 
verify the instrument’s validity. 
The participants were enrolled via a random 
convenience sampling method. Patients to the four 
primary care centers were approached while sitting in 
the waiting area. The investigator explained the 
purpose of study to each participant and obtained 
verbal and documented consent to participate in the 
study before administering the questionnaire. All data 
were coded, entered, and analyzed using the 
Statistical Package for the Social Sciences, version 23 
(SPSS 23). Continuous variables were reported in 
terms of means and standard deviation, while 
categorical variables were described using 
frequencies and percentages. Analytic statistics were 
performed using the chi-squared (
2
) test for 
associations and/or the difference between two 
categorical variables. A P value of ≤ 0.05 was 
considered statistically significant. 
Approval for the study was obtained from King 
Abdullah International Medical Research Center, the 
Ministry of the National Guard, Kingdom of Saudi 
Arabia. The participants were fully informed regarding 
voluntary participation, privacy, anonymity, and 
confidentiality of the data were ensured and the 
Declaration of Helsinki ethical rules were followed. 
 
 
Results 
 
Table 1 show that the majority of PHC 
patients included in the study were female (58.7%), 
while males made up 41.3% (Figure 1A). 
 
Table 1: Frequencies, distribution, and percentages of socio-
demographic variables 
VARIABLES  NO  %  
Sex    
Male 
Female 
165 
235 
41.3 
58.7 
Age   
Mean (SD) 
Min age 
Max age 
35.89 ± 12.04 
25 
66 
 
Occupation    
Student  
 Housewife  
 Government employee 
 Non-government employee 
 Unemployed 
 Retired  
43 
91 
124 
50 
72 
20 
10.8 
22.8 
31.0 
12.4 
18.0 
5.0 
Education    
Primary school  
 Middle school  
 High school 
 College 
 Graduated  
 Post-graduation studies 
 Can read and write name only  
 Non-literate 
 18 
10 
190 
23 
93 
21 
16 
29 
4.5 
2.5 
47.5 
5.8 
23.3 
5.3 
4.0 
7.3 
Marital status    
Single 
 Married 
 Widowed 
 Divorced 
131 
203 
22 
44 
32.8 
50.7 
5.5 
11.0 
No. of dependent family members   
0-1 
2-3 
4 
5 
6 
≥ 7 
169 
62 
35 
31 
56 
47 
42.3 
15.4 
8.8 
7.8 
14.0 
11.7 
 
The mean age of patients was 35.98 yrs. old 
(± 12.04) with most being government employees 
(31.0%), followed by housewives, the unemployed, 
non-government employees, students, and the retired 
at 22.8%, 18%, 12.4%, 10.8%, 5%, respectively 
(Figure 1B).  
The majority of PHC patients (47.5%) 
included in the study had some high school; they were 
followed by graduates, the non-literate, college 
students, post-graduates, primary school, those able 
to read and write only their names, and those with 
middle school at 23.3%, 7.3%, 5.8%, 5.3%, 4.5%, 4%, 
and 2.5%, respectively (Figure 1C). 
 
Figure 1: Distribution of visitors according to A) gender; B) 
occupation; C) education; D) marital status; E) number of 
dependents 
 
Most study participants were married (50.7%), 
while single, divorced, and widowed participants 
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constituted 32.8%, 11%, and 5.5%, respectively 
(Figure 1D). 
The majority of participants (42.3%) had no or 
only one dependent family member while those with 
2–3, 4, 5, 6, or equal to or more than seven made up 
15.4%, 8.8%, 7.8%, 14%, and 11.7% of the 
participants, respectively (Figure 1E). 
As shown in Table 2, 56.8% of patients had 
heard the term “SLE.” The most common way 
participants recognized the disease was from the 
internet (online resources) (35.2%) as the majority of 
them had not been diagnosed with SLE (85.5%).  
Table 2: Awareness of systemic lupus erythematosus 
frequencies and percentages 
NO Questions  N  %  
 
7 
Have you ever heard of the term “systemic lupus erythematosus”? 
Yes 
No 
Don’t know 
 
227 
148 
25 
 
56.8 
37.0 
6.50 
 
 
 
 
8 
Through which of the following sources did you hear about systemic lupus 
erythematosus? (You can choose more than one option) 
 Heard from a doctor  
 Internet/online resources 
 TV  
 Radio 
 Newspaper or magazines  
 Friend or colleague 
 Other (specify) ____________________________ 
 
 
31 
80 
11 
14 
8 
65 
18 
 
13.7 
35.2 
4.9 
6.2 
3.5 
28.6 
7.9 
 
9 
 Have you been diagnosed with systemic lupus erythematosus?  
 Yes 
 No 
 
58 
343 
 
14.5 
85.5 
 
10 
Do you know anyone who has systemic lupus erythematosus?  
 Family member  
 Relatives  
 Colleague  
 No one 
 Others (please specify) _________________________ 
 
 
44 
62 
46 
246 
2 
 
11.0 
15.5 
11.5 
61.5 
0.5 
 
 
 
11 
 Is systemic lupus erythematosus contagious? 
 
 Yes  
 No  
 Don’t know 
 
 
 
 
99 
108 
193 
 
 
 
 
24.8 
27.0 
48.2 
 
 
 
12 
 Is systemic lupus erythematosus fatal? 
 Yes  
 No  
 Don’t know 
 
 
141 
85 
174 
 
 
 
35.3 
21.2 
43.5 
 
 
 
13 
 
 Systemic lupus erythematosus is an autoimmune disease, which means: 
 There is no cause (the body fights itself)  
 There are tumors  
 It is hereditary 
 Don’t know  
 Other (please specify) __________________ 
 
 
103 
64 
119 
110 
4 
 
 
25.8 
16.0 
29.8 
27.4 
1.0 
 
 
14 
 Does systemic lupus erythematosus mostly affect females? 
 Yes  
 No  
 Don’t know 
 
 
156 
46 
198 
 
39.0 
11.5 
49.5 
 
15 
 
Does systemic lupus erythematosus affect any organ/part in the body?  
 Yes  
 No  
 Don’t know 
 
 
174 
48 
178 
 
43.5 
12.0 
44.5 
 
 
 
 
 
 
16 
 What organs can be affected by systemic lupus erythematosus? (You can choose more 
than one option) 
 Kidney  
 Blood  
 Heart  
 Eyes 
 Liver  
 Skin  
 Joints  
 Lungs 
 All of above  
 Don’t know  
 Others (Please specify) _______ 
 
106 
29 
23 
5 
47 
30 
3 
64 
92 
 
 
26.8 
7.3 
5.8 
1.3 
11.8 
7.5 
0.8 
16.0 
23.0 
 
 
 
 
 
 
17 
 The following are symptoms of systemic lupus erythematosus. 
 Rash  
 Alopecia  
 Joint pain  
 Hematuria  
 Photosensitivity  
 Don’t know 
 All of the above  
 
57 
42 
59 
9 
12 
114 
107 
 
14.3 
10.5 
14.8 
2.3 
3.0 
28.5 
26.8 
 
 
 
18 
 Systemic lupus erythematosus can be diagnosed with a single blood test. 
 Yes  
 No  
 Don’t know 
 
139 
95 
166 
 
34. 8 
23.7 
41.5 
 
19 
 Systemic lupus erythematosus can be prevented.  
 Yes  
 No  
 Don’t know 
 
162 
79 
159 
 
40.5 
19.7 
39.8 
 
20 
 Systemic lupus erythematosus is a treatable disease. 
 Yes  
 No  
 Don’t know 
 
165 
83 
152 
 
41.2 
20.8 
38.0 
 
21 
 Systemic lupus erythematosus is an illness with few complications. 
 Yes  
 No  
 Don’t know 
 
157 
82 
161 
 
39.2 
20.6 
40.2 
 
 
 
22 
 The treatment for of systemic lupus erythematosus is: 
 Chemotherapy  
 Steroids  
 Malaria medications 
 Combination of above medications  
 Others  
 Don’t know 
 
104 
73 
77 
47 
1 
98 
 
26.0 
18.2 
19.3 
11.7 
0.3 
24.5 
 
 
23 
 Can lupus erythematosus disease affect the fertility of men and women? 
 Yes  
 No  
 Don’t know 
165 
59 
176 
41.3 
14.8 
44.0 
 
24 
 Systemic lupus erythematosus causes fetal abnormalities or recurrent abortions in the 
affected mother. 
 Yes  
 No  
 Don’t know 
 
201 
52 
147 
 
50.3 
13.0 
36.7 
 
25 
 Should awareness of systemic lupus erythematosus be promoted? 
 Yes  
 No  
 Don’t know 
 
345 
9 
46 
 
86.3 
2.3 
11.4 
Most of the participants did not know anyone 
with SLE (61.5%) and the majority did not know that 
SLE is not contagious (48.2%) but could be fatal 
(43.5%). Most believed that SLE was a hereditary 
disease and classified SLE in this way (29.8%). 
The majority did not know SLE mostly affects 
females (49.5%). They also did not know that SLE can 
affect any organs in the body (44.5%). Indeed 26.8% 
believed that only the kidney could be affected by 
systemic lupus erythematosus. 
Most of the patients did not know the major 
symptoms of SLE (28.5%) and 41.5% did not know 
the main laboratory tests for SLE; 40.5% did not know 
whether SLE could be prevented although most 
believed that SLE is a treatable disease (41.2%).  
The majority of participants did not know the 
complications of SLE (40.2%) and 26% believed that 
a treatment of SLE was chemotherapy. Most did not 
know that SLE can affect the fertility of men and 
women (44.0%), although they knew that SLE causes 
fetal abnormalities or recurrent abortions in the 
affected mother (50.3%). 
Finally, the majority of participants believed 
that awareness of SLE should be promoted (86.3%); 
the score for awareness of SLE (n = 400) indicated 
that 64.7% of participant were unaware of SLE, while 
35.3% were aware of SLE. 
Table 3: Correlations between socio-demographic variables 
and awareness 
Socio-demographic 
variables  
Awareness of systemic lupus 
erythematosus 2 P value 
 
Aware Unaware 
No % No %   
Gender 
Male 
Female 
 
63 
58 
 
 
44.7 
54.9 
 
 
102 
157 
 
 
39.4 
60.6 
 
1.058 0.304 
Education 
Primary school  
Middle school  
High school 
College 
Graduated  
Post-graduation studies 
Can read and write name 
only  
Illiterate 
 
12 
28 
42 
21 
28 
10 
0 
0 
8.5 
19.9 
29.8 
14.9 
19.9 
7.1 
0 
0 
 
31 
63 
82 
29 
44 
10 
0 
0 
 
 
12.0 
24.3 
31.7 
11.2 
17.0 
309 
0 
0 
 
9.457 0.023* 
Do you know anyone who 
has systemic lupus 
erythematosus?  
Family member  
Relatives  
Colleague  
No one 
Others (please specify)  
16 
18 
15 
92 
0 
11.3 
12.8 
10.6 
65.2 
0 
28 
44 
31 
154 
2 
10.8 
17.0 
12.0 
59.5 
0.8 
10.082 0.020* 
 
Table 3 shows the correlations between 
socio-demographic variables (gender, education, do 
you know anyone who has systemic lupus 
erythematosus?) and awareness of SLE. Awareness 
about SLE by gender was not statistically significant 
(P = 0.304), but there was a statistically significant 
difference according to education level. Participants 
with high school education were more aware than 
those with a lower level of education (primary and 
middle school) (P = 0.023).  
Furthermore, there was a statistically 
Public Health 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2390                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
significant correlation between knowing a person with 
SLE and awareness (P = 0.020); this means that if the 
participants did not know a person with SLE before 
they will be unaware of SLE and its nature or 
manifestations. 
Thus, the major factors that affect SLE 
knowledge and attitude are education level and 
knowing someone who have been diagnosed 
previously with SLE and is coping with it.  
 
 
Discussion 
 
The main aim of this study was to assess the 
awareness of the patients in the primary heath care of 
KAMC about SLE, its clinical manifestations, 
diagnosis, treatment, complications, and comorbidities 
as well as explore the possible factors that influence 
SLE awareness, such as adequate health promotion 
and clinical awareness-raising.  
The study was carried out in four primary 
health care centers belonged to KAMC in Riyadh. The 
centers are the HCSC; King Abdulaziz Housing 
Clinics (Iskan); the NGCSC, and King Abdulaziz 
Housing Clinics (Dirab). As found in a similar local 
study [10], 40% have previously heard the term SLE. 
As well as the 2nd local study [13],  55.9% have 
previously heard the term SLE. 
The 400 participants in this study were 
chosen from the waiting area in the clinics using 
random convenience sampling. The fact that females 
are more frequently reported having the disease than 
males. This is attributable to the fact that women are 
more expected to get SLE than males. Most of the 
participants were government employees (31.0%) and 
the majority had studied at high school; 50.7% of 
participants were married with/without dependent 
family members. 
The study clarifies that 56.8% of participants 
had heard the term “systemic lupus erythematosus” 
and the most common way that they recognized the 
disease was through the internet (online resources). 
The vast majority had not been diagnosed 
with SLE and did not know that SLE is not contagious 
and fatal. However, they believed that the kidney is 
the only organ that can be affected by SLE. As found 
in a similar local study11, more than 50% of 
participant believed that SLE don’t have renal 
manifestation while some study conclude that one of 
major reason of death among SLE patients is renal 
failure.  
The onset of the disease is slow with new 
symptoms occurring over weeks, months, and 
sometimes years. The most common initial symptoms 
of lupus in patients are unspecified complaints of 
fatigue and health malaise. Many patients experience 
sporadic or persistent high temperatures with gradual 
loss of weight and poor appetite. Ultimately, patients 
progress to developing certain clinical symptoms 
because one or more parts of the body are affected. 
Skin and mucous membranes are usually the most 
affected by the disease. Symptoms may include 
various forms of skin rash, photosensitivity, and mouth 
ulcers. In one-third of the affected patients, the 
characteristic butterfly rash occurs in the center of a 
patient`s face [4], [5]. 
SLE has been found to have serious 
complications in previous studies, which range from 
renal failure to death. Early death is common in males 
with skin manifestations who are under 16 years old at 
the time of diagnosis while the possibility of late death 
is frequently seen in patients over 30 years at the time 
of diagnosis. Overall death was significantly high in 
older patients and in those with established kidney 
disease [6], [7]. 
In terms of SLE diagnostic patterns, the 
participants did not know the possible laboratory tests 
for diagnosing SLE; they believed that SLE is a 
treatable sickness where the main treatment is 
chemotherapy. Moreover, a great number did not 
know the minor or major complications of SLE. 
Diagnosis depends on the availability of a range of 
signs and symptoms with some laboratory tests 
involving blood and urine, and sometimes biopsy to 
exclude further disease. Symptoms and signs 
sometimes do not appear observable at any time, 
which makes it difficult to diagnose the disease in a 
timely manner. The American College of 
Rheumatology has listed 11 criteria to differentiate 
SLE from other diseases; if many of them are reported 
in clinical settings they may indicate the presence of 
SLE. This criterion roughly signifies the common 
clinical symptoms of people with this disease. To 
diagnose this disease, at least four of these 11 criteria 
must be met at any given time. However, experienced 
physicians are able to diagnose it even if patients 
present with fewer than four criteria. 
Most of the participants in our study were 
unaware of SLE. This indicates poor knowledge about 
the disease. There were no statistically significant 
differences in awareness about SLE between males 
and females (P = 0.304), but there was statistically 
significant differences according to education levels (P 
= 0.023), and between knowing a person who had 
been diagnosed with SLE and caring for him or her (P 
= 0.020). 
Finally, most participants believed that 
awareness of SLE should be promoted in the 
community, whether in hospitals or schools, to 
enhance knowledge about the disease and its nature 
in a different way; it was recommended that clinical 
workshops be conducted, short videotapes or medical 
flyers be used, and face-to-face discussions be held 
along with support groups and online resources.  
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Limitations: This study was geographically 
limited and only included the patients to primary 
healthcare clinics at KAMC in Riyadh. Therefore, it 
may not be possible to generalize the results. Recall 
bias is also possible. 
Recommendations:There is a need for public 
awareness activities to educate people about SLE, its 
clinical manifestations, diagnosis, treatment, and 
complications; although it is not a contagious disease 
that requires isolation, it may be fatal if neglected. 
In conclusion, the study shows that this 
survey is valuable and beneficial to the community as 
it helps people to assess their knowledge about SLE 
and become more aware of the disease.  
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